anaphylactic reactions (Generalised pruritus, Urticaria, Dizziness, Nausea and Asthenia); This literature-non-study case was reported in a literature article and describes the occurrence of ANAPHYLACTIC REACTION (anaphylactic reactions (Generalised pruritus, Urticaria, Dizziness, Nausea and Asthenia)) in a 34-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.       Concurrent medical conditions included Allergy to intravenous contrast media (allergy to intravenous contract).   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ANAPHYLACTIC REACTION (anaphylactic reactions (Generalised pruritus, Urticaria, Dizziness, Nausea and Asthenia)) (seriousness criterion medically significant). At the time of the report, ANAPHYLACTIC REACTION (anaphylactic reactions (Generalised pruritus, Urticaria, Dizziness, Nausea and Asthenia)) outcome was unknown. Possible    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Tryptase: 6/not done(nd) reaction/basal (ug/L)- 6/ND.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered ANAPHYLACTIC REACTION (anaphylactic reactions (Generalised pruritus, Urticaria, Dizziness, Nausea and Asthenia)) to be possibly related.    No concomitant information were reported. Treatment information was not provided.  Anaphylaxis for Brighton Criteria was Level 2, NIAAD Criteria was Yes PEG challenge was not done. Patient had tolerated 1st dose and reaction occurred after the 2nd dose  This case concerns a 34-year-old patient of unknown gender with a relevant medical history of Contrast media allergy, who experienced the expected serious event of Anaphylactic reaction after mRNA- 1273 Moderna vaccine (Moderna COVID-19 Vaccine / Spikevax). The event occurred after the second dose of mRNA- 1273 vaccine, precise temporal relationship unknown. Clinical manifestations included Generalised pruritus, Urticaria, Dizziness, Nausea and Asthenia. Brighton Criteria for Anaphylaxis was Level 2, NIAAD Criteria was Yes. The rechallenge is not applicable, since the event was reported exclusively after the second dose. Previous hisotry of contrast media allergy remains a confounder. The benefit-risk relationship of mRNA- 1273 vaccine / Moderna COVID-19 Vaccine is not affected by this report.   This case was linked to MOD-2021-372464, MOD-2021-372465, MOD-2021-372371 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 03-Nov-2021: Follow up received by safety on 04-Nov-2021 included an Email; Sender's Comments: This case concerns a 34-year-old patient of unknown gender with a relevant medical history of Contrast media allergy, who experienced the expected serious event of Anaphylactic reaction after mRNA- 1273 Moderna vaccine (Moderna COVID-19 Vaccine / Spikevax). The event occurred after the second dose of mRNA- 1273 vaccine, precise temporal relationship unknown. Clinical manifestations included Generalised pruritus, Urticaria, Dizziness, Nausea and Asthenia. Brighton Criteria for Anaphylaxis was Level 2, NIAAD Criteria was Yes. The rechallenge is not applicable, since the event was reported exclusively after the second dose. Previous hisotry of contrast media allergy remains a confounder. The benefit-risk relationship of mRNA- 1273 vaccine / Moderna COVID-19 Vaccine is not affected by this report.